Masashi Miyamoto to be named Chairman and CEO Abdul Mullick to be named President and COO Changes designed to further deliver on company's 2030 Vision and commitment to advancing novel treatments for Bone/Mineral, Intractable Hematological Diseases/Hemato-Oncology and Rare Diseases TOKYO , Oct. 31, 2024 /PRNewswire/ -- Japan -based Global Specialty Pharmaceutical Company Kyowa Kirin Co., Ltd.
(President and CEO: Masashi Miyamoto ) today announced that Masashi Miyamoto , Ph.D. will take the role of Chairman and CEO, after serving as President for the past 7 years.
Abdul Mullick , Ph.D., the current Chief International Business Officer (CIBO), will become President and Chief Operating Officer.
The changes will come into effect following approval at the Ordinary General Meeting of Shareholders and the Board of Directors meeting in March 2025 . These changes reflect a new dual CEO-COO leadership structure to help support the business' continued growth. Miyamoto, as Chairman and CEO, will lead discussions on Kyowa Kirin's direction and overall strategy and maintain key relationships with stakeholders, while Mullick, as President and COO, will oversee the execution of all business operations at the global level, enhancing collaboration across regions and functions and advancing the management strategy.
Additional details regarding the structure will be shared post-approval. "Our vision for 2030 is to deliver life-changing value to patients in our focus disease areas, by leveraging .
